Lv5
890 积分 2023-11-08 加入
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)
14天前
已关闭
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvement
27天前
已关闭
Interleukin-6 is a highly prognostic biomarker for POEMS syndrome
9个月前
已关闭
Acute promyelocytic leukemia with <i>TTMV::RARA</i> fusion potentially responds to all-trans retinoic acid/arsenic trioxide treatment
10个月前
已完结
皖公网安备34019202002308
